Get the latest news, insights, and market updates on HRMY (Harmony Biosciences Holdings, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
PLYMOUTH MEETING, Pa., November 24, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resistant (GR) formulation. With positive findings from both the pivotal BE and dosing optimization studies, Harmony is on track to submit a New Drug Application (NDA) for pitolisant GR in early 2026, targeting a PDUFA date in Q1 2027. With utility patent applications filed for pitolisant GR with poten Nov 24, 2025 - $HRMY
Harmony Biosciences to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., November 18, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Nov 18, 2025 - $HRMY
Raised Revenue Guidance and Strong Q3 Results Could Be a Game Changer for Harmony Biosciences (HRMY)
On November 4, 2025, Harmony Biosciences Holdings reported third quarter net income of US$50.87 million, up from US$46.09 million the previous year, and raised its full-year 2025 revenue guidance to US$845–865 million. This increase in both profitability and revenue outlook highlights the company’s momentum in commercial execution and ongoing demand for its products. We'll explore how Harmony Biosciences’ raised revenue guidance shapes the updated investment narrative and outlook for future... Nov 5, 2025 - $HRMY
Harmony Biosciences (HRMY) Margin Expansion Reinforces Bullish Value Narrative
Harmony Biosciences Holdings (HRMY) reported a net profit margin of 22.5%, up from 18% last year, showcasing improved profitability. Over the past year, earnings surged 51.4%, well ahead of the company’s five-year average growth rate of 40.8%. Forecasts call for a further 20.5% annual earnings growth over the next three years. With revenue expected to grow at 12.7% annually and a price-to-earnings ratio of 9.5x, which stands well below industry peers, investors may see these numbers as... Nov 5, 2025 - $HRMY
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
PLYMOUTH MEETING, Pa., November 04, 2025--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. These results were driven by the highest ever increase in average number of patients of approximately 500 for the quarter, accelerating the trajectory toward blockbuster status for WAKIX in narcolepsy. The company continues to build on four consecutive years of revenue growth and profitability. With Nov 4, 2025 - $HRMY
Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. On October 24, Danielle Brill from Truist Financial reiterated a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) without disclosing any price targets. The rating follows the company’s pre-announcement of strong Q3 2025 WAKIX performance on […] Nov 1, 2025 - $HRMY
Is Harmony Biosciences’ Progress on Lead Treatment Signaling a New Valuation Opportunity?
Are you watching Harmony Biosciences Holdings and wondering whether now is the moment to make your move? Over the past week, the stock has leapt 13.3%, catching the eye of both longtime holders and would-be buyers seeking the next turning point. Longer term, though, it has been a rougher ride. The stock remains down nearly 15% for the year and, looking at a three-year view, has given up half its value. Still, those who have followed the recent developments surrounding the company see reasons... Oct 29, 2025 - $HRMY
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple